Accession Number : AD1047899


Title :   Prostate Cancer Clinical Consortium Clinical Research Site: Targeted Therapies


Descriptive Note : Technical Report,30 Sep 2016,29 Sep 2017


Corporate Author : Weill Medical College of Cornell University New York United States


Personal Author(s) : Nanus, David


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1047899.pdf


Report Date : 01 Oct 2017


Pagination or Media Count : 28


Abstract : The Weill Cornell Medical College Prostate Cancer Research Program (WCMC-PCRP) is a Clinical Research Site of the Prostate Cancer Clinical Trials Consortium (PCCTC). The purpose of the research is to lead and participle in Consortium therapeutic and correlative science research protocols. Specifically, our aims are to impact prostate cancer care and outcomes through the development and study of novel targeted therapeutics, discovery of mechanisms of therapy resistance/sensitivity, identification of new therapeutic targets through high quality genomic analyses, providing access to the highest quality PC tissue specimens, and development of molecular imaging techniques with direct relevance to targeted therapies. Our overarching goal is to more effectively bring novel agents and new biomarker driven trials directly to patients.


Descriptors :   Prostate cancer , clinical trials , biomedical research , genomics , tissues (biology) , sampling , therapy , KINASES , antibodies


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE